For example, a clinical trial on advanced renal cancer revealed that pembrolizumab (PD-L1 monoclonal antibody) combined with axitinib leads to greater risks of proteinuria and is more prone to renal damage [136]. The gene discussed is CD274; the disease is renal carcinoma.